Company intelligence / Profile preview

Lahjavida, Inc.

Colorado Springs, Colorado, United Stateslahjavida.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lahjavida has developed proprietary technology that combines tumor-targeting dyes with chemotherapy drugs, showing promise in selectively eliminating cancer cells. The company is seeking funding to demonstrate compound accumulation in tumors and radiowave treatment efficacy in animal models.

Therapeutic areas: Oncology
Modalities: Dye Drug Conjugates (DDCs)
Industry: Biotech

Drug pipeline

1 asset

HCC-MMAE

Preclinical

Partnerships

University of Colorado, Colorado SpringsDr. Anatoliy Pinchuk's laboratory

Beyond the preview

Go deeper on Lahjavida, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lahjavida, Inc..

Explore the full profile